The TBS has been successfully applied in various forms of osteoporosis (e.g. in post-menopausal women, patients with diabetes, individuals receiving glucocorticoid therapy, patients with endogenous Cushing’s syndrome, those on hemodialysis, and breast cancer survivors taking aromatase inhibitors), particularly as a complement to BMD. The gene discussed is CYP19A1; the disease is diabetes mellitus.